Protein-protein interactions of viroporins in coronaviruses and paramyxoviruses: New targets for antivirals?

Viruses

Volumn 7, Issue 6, 2015, Pages 2858-2883

  Torres, Jaume ^a   Surya, Wahyu ^a   Li, Yan ^a   Liu, Ding Xiang ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Coronavirus; Cytoplasmic helical domains; Envelope protein; Protein protein interactions; Respiratory syncytial virus; Small hydrophobic protein

Indexed keywords

ANTIVIRUS AGENT; ENVELOPE PROTEIN; ONCOPROTEIN; PORIN; PROTEIN BINDING; SMALL HYDROPHOBIC PROTEIN, VIRUS; VIRUS ENVELOPE PROTEIN;

APOPTOSIS; CHEMICAL PHENOMENA; CORONAVIRIDAE; GENE OVEREXPRESSION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUTATION; NONHUMAN; PARAMYXOVIRIDAE; PHENOTYPE; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE DELETION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; PARAMYXOVIRINAE; PHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN CONFORMATION; TWO HYBRID SYSTEM;

CORONAVIRUS; RESPIRATORY SYNCYTIAL VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CORONAVIRUS; GENE DELETION; HUMANS; PARAMYXOVIRINAE; PORINS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING; RETROVIRIDAE PROTEINS, ONCOGENIC; TWO-HYBRID SYSTEM TECHNIQUES; VIRAL ENVELOPE PROTEINS;

EID: 84930944068     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7062750     Document Type: Review

References (172)

1. Enjuanes, L.; Brian, D.; Cavanagh, D.; Holmes, K.; Lai, M.M.C.; Laude, H.; Masters, P.; Rottier, P.; Siddell, S.G.; Spaan, W.J.M.; et al. Coronaviridae. In Virus taxonomy. Classification and Nomenclature of Viruses; van Regenmortel, M.H.V., Fauquet, C.M., Bishop, D.H.L., Carsten, E.B., Estes, M.K., Lemon, S.M., McGeoch, D.J., Maniloff, J., Mayo, M.A., Pringle, C.R., et al, Eds.; Academic Press: San Diego, CA, USA, 2000; pp. 835–849.
2. Woo, P.C.Y.; Lau, S.K.P.; Huang, Y.; Yuen, K.Y. Coronavirus Diversity, Phylogeny and Interspecies Jumping. Exp. Biol. Med. 2009, 234, 1117–1127.
3. De Groot, R.J.; Baker, S.C.; Baric, R.; Enjuanes, L.; Gorbalenya, A.E.; Holmes, K.V.; Perlman, S.; Poon, L.; Rottier, P.J.M.; Talbot, P.J.; et al. Family Coronaviridae. In Virus Taxonomy, Ninth Report of the International Committee on Taxonomy of Viruses; King, A.M.Q., Adams, M.J., Carstens, E.B., Lefkowitz, E.J., Eds.; Elsevier: Oxford, UK, 2011; pp. 29, 806–828.
4. Beaudette, F.R.; Hudson, C.B. Cultivation of the virus of infectious bronchitis. J. Am. Vet. Med. Assoc. 1937, 90, 51–60.
5. Tyrrell, D.A.; Bynoe, M.L. Cultivation of a novel type of common cold virus in organ cultures. Br. Med. J. 1965, 1, 1467–1470.
6. Holmes, K.V. SARS coronavirus: A new challenge for prevention and therapy. J. Clin. Investig. 2003, 111, 1605–1609.
7. Raj, V.S.; Osterhaus, A.D.M.E.; Fouchier, R.A.M.; Haagmans, B.L. MERS: Emergence of a novel human coronavirus. Curr. Opin. Virol. 2014, 5, 58–62.
8. Lou, Z.; Sun, Y.; Rao, Z. Current progress in antiviral strategies. Trends Pharmacol. Sci. 2014, 35, 86–102.
9. Kilianski, A.; Baker, S.C. Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors. Antivir. Res. 2014, 101, 105–112.
10. Kilianski, A.; Mielech, A.M.; Deng, X.; Baker, S.C. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors. J. Virol. 2013, 87, 11955–11962.
11. Graham, R.L.; Becker, M.M.; Eckerle, L.D.; Bolles, M.; Denison, M.R.; Baric, R.S. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat. Med. 2012, 18, 1820–1826.
12. Enjuanes, L.; Nieto-Torres, J.L.; Jimenez-Guardeno, J.M.; DeDiego, M.L. Recombinant Live Vaccines to Protect against the Severe Acute Respiratory Syndrome Coronavirus. In Replicating Vaccines, Birkhauser Advances in Infectious Diseases; Dormitzer, P., Mandl, C.W., Rappuoli, R., Eds.; Springer: Basel, Switzerland, 2011; pp. 73–97.
13. Heald-Sargent, T.; Gallagher, T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses 2012, 4, 557–580.
14. Masters, P.S. The molecular biology of coronaviruses. Adv. Virus Res. 2006, 66, 193–292.
15. Liu, D.X.; Fung, T.S.; Chong, K.; Shukla, A.; Hilgenfeld, R. Accessory proteins of SARS-CoV and other coronaviruses. Antivir. Res. 2014, 109, 97–109.
16. Liu, D.X.; Cavanagh, D.; Green, P.; Inglis, S.C. A Polycistronic Messenger-RNA Specified by the Coronavirus Infectious-Bronchitis Virus. Virology 1991, 184, 531–544.
17. Godet, M.; L’Haridon, R.; Vautherot, J.-F.; Laude, H. TGEV corona virus ORF4 encodes a membrane protein that is incorporated into virions. Virology 1992, 188, 666–675.
18. Yu, X.; Bi, W.; Weiss, S.R.; Leibowitz, J.L. Mouse hepatitis virus gene 5b protein is a new virion envelope protein. Virology 1994, 202, 1018–1023.
19. Liao, Y.; Yuan, Q.; Torres, J.; Tam, J.P.; Liu, D.X. Biochemical and functional characterization of the membrane association and membrane permeabilizing activity of the severe acute respiratory syndrome coronavirus envelope protein. Virology 2006, 349, 264–275.
20. Corse, E.; Machamer, C.E. Infectious bronchitis virus E protein is targeted to the Golgi complex and directs release of virus-like particles. J. Virol. 2000, 74, 4319–4326.
21. Liu, D.X.; Inglis, S.C. Association of the infectious bronchitis virus 3c protein with the virion envelope. Virology 1991, 185, 911–917.
22. Tung, F.Y.T.; Abraham, S.; Sethna, M.; Hung, S.-L.; Sethna, P.; Hogue, B.G.; Brian, D.A. The 9-kDa hydrophobic protein encoded at the 3′ end of the porcine transmissible gastroenteritis coronavirus genome is membrane-associated. Virology 1992, 186, 676–683.
23. Corse, E.; Machamer, C.E. The cytoplasmic tails of infectious bronchitis virus E and M proteins mediate their interaction. Virology 2003, 312, 25–34.
24. Raamsman, M.J.B.; Krijnse Locker, J.; de Hooge, A.; de Vries, A.A.F.; Griffiths, G.; Vennema, H.; Rottier, P.J.M. Characterization of the coronavirus mouse hepatitis virus strain A59 small membrane protein E. J. Virol. 2000, 74, 2333–2342.
25. Lopez, L.A.; Riffle, A.J.; Pike, S.L.; Gardner, D.; Hogue, B.G. Importance of conserved cysteine residues in the coronavirus envelope protein. J. Virol. 2008, 82, 3000–3010.
26. Nieto-Torres, J.L.; DeDiego, M.L.; Alvarez, E.; Jimenez-Guardeno, J.M.; Regla-Nava, J.A.; Llorente, M.; Kremer, L.; Shuo, S.; Enjuanes, L. Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. Virology 2011, 415, 69–82.
27. Liu, D.X.; Yuan, Q.; Liao, Y. Coronavirus envelope protein: A small membrane protein with multiple functions. Cell. Mol. Life Sci. 2007, 64, 2043–2048.
28. DeDiego, M.L.; Nieto-Torres, J.L.; Jimenez-Guardeno, J.M.; Regla-Nava, J.A.; Alvarez, E.; Oliveros, J.C.; Zhao, J.; Fett, C.; Perlman, S.; Enjuanes, L. Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis. PLoS Pathog. 2011, 7, e1002315.
29. DeDiego, M.L.; Nieto-Torres, J.L.; Regla-Nava, J.A.; Jimenez-Guardeño, J.M.; Fett, C.; Fernandez-Delgado, R.; Castaño-Rodriguez, C.; Perlman, S.; Enjuanes, L. Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J. Virol. 2014, 88, 913–924.
30. Lamirande, E.W.; DeDiego, M.L.; Roberts, A.; Jackson, J.P.; Alvarez, E.; Sheahan, T.; Shieh, W.J.; Zaki, S.R.; Baric, R.; Enjuanes, L.; et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J. Virol. 2008, 82, 7721–7724.
31. Netland, J.; DeDiego, M.L.; Zhao, J.; Fett, C.; Alvarez, E.; Nieto-Torres, J.L.; Enjuanes, L.; Perlman, S. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 2010, 399, 120–128.
32. Almazán, F.; DeDiego, M.L.; Sola, I.; Zuñiga, S.; Nieto-Torres, J.L.; Marquez-Jurado, S.; Andrés, G.; Enjuanes, L. Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate. MBio 2013, 4, e00650-13.
33. Regla-Nava, J.A.; Nieto-Torres, J.L.; Jimenez-Guardeño, J.M.; Fernandez-Delgado, R.; Fett, C.; Castaño-Rodríguez, C.; Perlman, S.; Enjuanes, L.; de Diego,M.L., Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates. J. Virol. 2015, 89, 3870–3887.
34. Nieto-Torres, J.L.; Dediego, M.L.; Verdia-Baguena, C.; Jimenez-Guardeno, J.M.; Regla-Nava, J.A.; Fernandez-Delgado, R.; Castano-Rodriguez, C.; Alcaraz, A.; Torres, J.; Aguilella, V.M.; et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. 2014, 10, e1004077.
35. Ruch, T.R.; Machamer, C.E. A single polar residue and distinct membrane topologies impact the function of the infectious bronchitis coronavirus E protein. PLoS Pathog. 2012, 8, e1002674.
36. Ruch, T.R.; Machamer, C.E. The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus. J. Virol. 2011, 85, 675–685.
37. Lavi, E.; Wang, Q.; Weiss, S.R.; Gonatas, N.K. Syncytia formation induced by coronavirus infection is associated with fragmentation and rearrangement of the Golgi apparatus. Virology 1996, 221, 325–334.
38. Ulasli, M.; Verheije, M.H.; de Haan, C.A.M.; Reggiori, F. Qualitative and quantitative ultrastructural analysis of the membrane rearrangements induced by coronavirus. Cell. Microbiol. 2010, 12, 844–861.
39. Ruch, T.R.; Machamer, C.E. The coronavirus E protein: Assembly and beyond. Viruses 2012, 4, 363–382.
40. Torres, J. Nanyang Technological University, Singapore, Unpublished work. 2015.
41. Torres, J.; Wang, J.; Parthasarathy, K.; Liu, D.X. The transmembrane oligomers of coronavirus protein E. Biophys. J. 2005, 88, 1283–1290.
42. Torres, J.; Parthasarathy, K.; Lin, X.; Saravanan, R.; Kukol, A.; Liu, D.X. Model of a putative pore: The pentameric α-helical bundle of SARS coronavirus E protein in lipid bilayers. Biophys. J. 2006, 91, 938–947.
43. Parthasarathy, K.; Ng, L.; Lin, X.; Liu, D.X.; Pervushin, K.; Gong, X.; Torres, J. Structural flexibility of the pentameric SARS coronavirus envelope protein ion channel. Biophys. J. 2008, 95, L39–L41.
44. Parthasarathy, K.; Lu, H.; Surya, W.; Vararattanavech, A.; Pervushin, K.; Torres, A. Expression and purification of coronavirus envelope proteins using a modified beta-barrel construct. Prot. Exp. Purif. 2012, 85, 133–141.
45. Li, Y.; Surya, W.; Claudine, S.; Torres, J. Structure of a Conserved Golgi Complex-targeting Signal in Coronavirus Envelope Proteins. J. Biol. Chem. 2014, 289, 12535–12549.
46. Pervushin, K.; Tan, E.; Parthasarathy, K.; Lin, X.; Jiang, F.L.; Yu, D.; Vararattanavech, A.; Soong, T.W.; Liu, D.X.; Torres, J. Structure and inhibition of the SARS coronavirus envelope protein ion channel. PLoS Pathog. 2009, 5, e1000511.
47. Surya, W.; Li, Y.; Verdià-Bàguena, C.; Aguilella, V.M.; Torres, J. MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels. Virus Res. 2015, 201, 61–66.
48. Verdia-Baguena, C.; Nieto-Torres, J.L.; Alcaraz, A.; DeDiego, M.L.; Torres, J.; Aguilella, V.M.; Enjuanes, L. Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids. Virology 2012, 432, 485–494.
49. Wilson, L.; Gage, P.; Ewart, G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology 2006, 353, 294–306.
50. Maeda, J.; Repass, J.F.; Maeda, A.; Makino, S. Membrane topology of coronavirus E protein. Virology 2001, 281, 163–169.
51. Yuan, Q.; Liao, Y.; Torres, J.; Tam, J.P.; Liu, D.X. Biochemical evidence for the presence of mixed membrane topologies of the Severe Acute Respiratory Syndrome coronavirus envelope protein expressed in mammalian cells. FEBS Lett. 2006, 580, 3192–3200.
52. Torres, J.; Maheswari, U.; Parthasarathy, K.; Ng, L.F.; Liu, D.X.; Gong, X.D. Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein Sci. 2007, 16, 2065–2071.
53. Gan, S.W.; Vararattanavech, A.; Nordin, N.; Eshaghi, S.; Torres, J.A cost-effective method for simultaneous homo-oligomeric size determination and monodispersity conditions for membrane proteins. Anal. Biochem. 2011, 416, 100–106.
54. Ramjeesingh, M.; Huan, L.J.; Garami, E.; Bear, C.E. Novel method for evaluation of the oligomeric structure of membrane proteins. Biochem. J. 1999, 342 Pt 1, 119–123.
55. Surya, W.; Samsó, M.; Torres, J. Structural and Functional Aspects of Viroporins in Human Respiratory Viruses: Respiratory Syncytial Virus and Coronaviruses. In Respiratory Disease and Infection-A New Insight; Vats, M., Ed.; InTech: Rijeka, Croatia, 2013; pp. 47–76.
56. Ghosh, A.; Pithadia, A.S.; Bhat, J.; Bera, S.; Midya, A.; Fierke, C.A.; Ramamoorthy, A.; Bhunia, A. Self-Assembly of a Nine-Residue Amyloid-Forming Peptide Fragment of SARS Corona Virus E-Protein: Mechanism of Self Aggregation and Amyloid-Inhibition of hIAPP. Biochemistry 2015, 54, 2249–2261.
57. Cohen, J.R.; Lin, L.D.; Machamer, C.E. Identification of a Golgi complex-targeting signal in the cytoplasmic tail of the severe acute respiratory syndrome coronavirus envelope protein. J. Virol. 2011, 85, 5794–5803.
58. Hernandez, L.D.; White, J.M. Mutational analysis of the candidate internal fusion peptide of the avian leukosis and sarcoma virus subgroup A envelope glycoprotein. J. Virol. 1998, 72, 3259–3267.
59. Ito, H.; Watanabe, S.; Sanchez, A.; Whitt, M.A.; Kawaoka, Y. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J. Virol. 1999, 73, 8907–8912.
60. Wolfsberg, T.G.; Straight, P.D.; Gerena, R.L.; Huovila, A.P.; Primakoff, P.; Myles, D.G.; White, J.M. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev. Biol. 1995, 169, 378–383.
61. Perry, A.C.; Gichuhi, P.M.; Jones, R.; Hall, L. Cloning and analysis of monkey fertilin reveals novel alpha subunit isoforms. Biochem. J. 1995, 307, 843–850.
62. Whitt, M.A.; Zagouras, P.; Crise, B.; Rose, J.K. A fusion-defective mutant of the vesicular stomatitis virus glycoprotein. J. Virol. 1990, 64, 4907–4913.
63. Kielian, M.; Rey, F.A. Virus membrane-fusion proteins: More than one way to make a hairpin. Nat. Rev. 2006, 4, 67–76.
64. Rey, F.A.; Heinz, F.X.; Mandl, C.; Kunz, C.; Harrison, S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995, 375, 291–298.
65. Root, M.J.; Steger, H.K. HIV-1 gp41 as a target for viral entry inhibition. Curr. Pharm. Des. 2004, 10, 1805–1825.
66. Langosch, D.; Hofmann, M.; Ungermann, C. The role of transmembrane domains in membrane fusion. Cell. Mol. Life Sci. 2007, 64, 850–864.
67. Armstrong, R.T.; Kushnir, A.S.; White, J.M. The transmembrane domain of influenza hemagglutinin exhibits a stringent length requirement to support the hemifusion to fusion transition. J. Cell Biol. 2000, 151, 425–437.
68. Odell, D.; Wanas, E.; Yan, J.; Ghosh, H.P. Influence of membrane anchoring and cytoplasmic domains on the fusogenic activity of vesicular stomatitis virus glycoprotein G. J. Virol. 1997, 71, 7996–8000.
69. Giraudo, C.G.; Hu, C.; You, D.; Slovic, A.M.; Mosharov, E.V.; Sulzer, D.; Melia, T.J.; Rothman, J.E. SNAREs can promote complete fusion and hemifusion as alternative outcomes. J. Cell Biol. 2005, 170, 249–260.
70. Hofmann, M.W.; Peplowska, K.; Rohde, J.; Poschner, B.C.; Ungermann, C.; Langosch, D. Self-interaction of a SNARE transmembrane domain promotes the hemifusion-to-fusion transition. J. Mol. Biol. 2006, 364, 1048–1060.
71. Roy, R.; Peplowska, K.; Rohde, J.; Ungermann, C.; Langosch, D. Role of the Vam3p transmembrane segment in homodimerization and SNARE complex formation. Biochemistry 2006, 45, 7654–7660.
72. Langosch, D.; Crane, J.M.; Brosig, B.; Hellwig, A.; Tamm, L.K.; Reed, J. Peptide mimics of SNARE transmembrane segments drive membrane fusion depending on their conformational plasticity. J. Mol. Biol. 2001, 311, 709–721.
73. Dennison, S.M.; Greenfield, N.; Lenard, J.; Lentz, B.R. VSV transmembrane domain (TMD) peptide promotes PEG-mediated fusion of liposomes in a conformationally sensitive fashion. Biochemistry 2002, 41, 14925–14934.
74. Cleverley, D.Z.; Lenard, J. The transmembrane domain in viral fusion: Essential role for a conserved glycine residue in vesicular stomatitis virus G protein. Proc. Nat. Acad. Sci. USA 1998, 95, 3425–3430.
75. Chellgren, B.W.; Creamer, T.P. Side-chain entropy effects on protein secondary structure formation. Proteins 2006, 62, 411–420.
76. Fischer, F.; Stegen, C.F.; Masters, P.S.; Samsonoff, W.A. Analysis of constructed E gene mutants of mouse hepatitis virus confirms a pivotal role for E protein in coronavirus assembly. J. Virol. 1998, 72, 7885–7894.
77. Corse, E.; Machamer, C.E. The cytoplasmic tail of infectious bronchitis virus E protein directs Golgi targeting. J. Virol. 2002, 76, 1273–1284.
78. Lamirande, E.W.; Dediego, M.L.; Roberts, A.; Jackson, J.P.; Alvarez, E.; Sheahan, T.; Shieh, W.J.; Zaki, S.R.; Baric, R.; Enjuanes, L.; et al. A live attenuated SARS coronavirus is immunogenic and efficacious in golden Syrian hamsters. J. Virol. 2008, 82, 7721–7724.
79. Siu, Y.L.; Teoh, K.T.; Lo, J.; Chan, C.M.; Kien, F.; Escriou, N.; Tsao, S.W.; Nicholls, J.M.; Altmeyer, R.; Peiris, J.S.; et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J. Virol. 2008, 82, 11318–11330.
80. Vennema, H.; Godeke, G.J.; Rossen, J.W.; Voorhout, W.F.; Horzinek, M.C.; Opstelten, D.J.; Rottier, P.J. Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes. EMBO J. 1996, 15, 2020–2028.
81. Ho, Y.; Lin, P.H.; Liu, C.Y.Y.; Lee, S.P.; Chao, Y.C. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem. Biophys. Res. Commun. 2004, 318, 833–838.
82. Lim, K.P.; Liu, D.X. The missing link in coronavirus assembly. Retention of the avian coronavirus infectious bronchitis virus envelope protein in the pre-Golgi compartments and physical interaction between the envelope and membrane proteins. J. Biol. Chem. 2001, 276, 17515–17523.
83. Hogue, B.G.; Machamer, C.E. Coronavirus structural proteins and virus assembly. In Nidoviruses; Perlman, S., Gallagher, T., Snijder, E.J., Eds.; ASM Press: Washington, DC, USA, 2008; pp. 179–200.
84. De Haan, C.A.; Vennema, H.; Rottier, P.J. Assembly of the coronavirus envelope: Homotypic interactions between the M proteins. J. Virol. 2000, 74, 4967–4978.
85. Rottier, P.J.M. The Coronaviridae; Siddell, S.G., Ed.; Plenum: New York, NY, USA, 1995; pp. 115–139.
86. Baudoux, P.; Carrat, C.; Besnardeau, L.; Charley, B.; Laude, H. Coronavirus pseudoparticles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. J. Virol. 1998, 72, 8636–8643.
87. Kuo, L.; Masters, P.S. Evolved variants of the membrane protein can partially replace the envelope protein in murine coronavirus assembly. J. Virol. 2010, 84, 12872–12885.
88. Teoh, K.T.; Siu, Y.L.; Chan, W.L.; Schluter, M.A.; Liu, C.J.; Peiris, J.S.; Bruzzone, R.; Margolis, B.; Nal, B. The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis. Mol. Biol. Cell 2010, 21, 3838–3852.
89. Jimenez-Guardeno, J.M.; Nieto-Torres, J.L.; DeDiego, M.L.; Regla-Nava, J.A.; Enjuanes, L.; Fernandez-Delgado, R.; Castano-Rodriguez, C. The PDZ-Binding Motif of Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Is a Determinant of Viral Pathogenesis. PLoS Pathog. 2014, 10, e1004320.
90. Ye, F.; Zhang, M.J. Structures and target recognition modes of PDZ domains: Recurring themes and emerging pictures. Biochem. J. 2013, 455, 1–14.
91. Wang, C.K.; Pan, L.F.; Chen, J.; Zhang, M.J. Extensions of PDZ domains as important structural and functional elements. Protein Cell 2010, 1, 737–751.
92. Penkert, R.R.; DiVittorio, H.M.; Prehoda, K.E. Internal recognition through PDZ domain plasticity in the Par-6-Pals1 complex. Nat. Struct. Mol. Biol. 2004, 11, 1122–1127.
93. Hillier, B.J.; Christopherson, K.S.; Prehoda, K.E.; Bredt, D.S.; Lim, W.A. Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex. Science 1999, 284, 812–815.
94. DiVittorio, H.; Penkert, R.; Prehoda, K.E. Mechanism of PDZ internal peptide recognition: Bypassing the requirement for a C-terminus. Protein Sci. 2004, 13, 138–138.
95. Kumar, S.; Boehm, J.; Lee, J.C. p38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2003, 2, 717–726.
96. Smits, S.L.; de Lang, A.; van den Brand, J.M.A.; Leijten, L.M.; van IJcken, W.F.; Eijkemans, M.J.C.; van Amerongen, G.; Kuiken, T.; Andeweg, A.C.; Osterhaus, A.D.M.E.; et al. Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates. PLoS Pathog. 2010, 6, e1000756.
97. Javier, R.T.; Rice, A.P. Emerging Theme: Cellular PDZ Proteins as Common Targets of Pathogenic Viruses. J. Virol. 2011, 85, 11544–11556.
98. Ji, H.L.; Song, W.; Gao, Z.; Su, X.F.; Nie, H.G.; Jiang, Y.; Peng, J.B.; He, Y.X.; Liao, Y.; Zhou, Y.J.; et al. SARS-CoV proteins decrease levels and activity of human ENaC via activation of distinct PKC isoforms. Am. J. Physiol.-Lung Cell. Mol. Physiol. 2009, 296, L372–L383.
99. Wetherill, L.F.; Holmes, K.K.; Verow, M.; Muller, M.; Howell, G.; Harris, M.; Fishwick, C.; Stonehouse, N.; Foster, R.; Blair, G.E.; et al. High-Risk Human Papillomavirus E5 Oncoprotein Displays Channel-Forming Activity Sensitive to Small-Molecule Inhibitors. J. Virol. 2012, 86, 5341–5351.
100. Goldstein, D.J.; Finbow, M.E.; Andresson, T.; Mclean, P.; Smith, K.; Bubb, V.; Schlegel, R. Bovine Papillomavirus-E5 Oncoprotein Binds to the 16k Component of Vacuolar H+-Atpases. Nature 1991, 352, 347–349.
101. Schapiro, F.; Sparkowski, J.; Adduci, A.; Suprynowicz, F.; Schlegel, R.; Grinstein, S. Golgi alkalinization by the papillomavirus E5 oncoprotein. J. Cell Biol. 2000, 148, 305–315.
102. Blount, R.E., Jr.; Morris, J.A.; Savage, R.E. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Biol. Med. 1956, 92, 544–549.
103. Dowell, S.F.; Anderson, L.J.; Gary, H.E., Jr.; Erdman, D.D.; Plouffe, J.F.; File, T.M., Jr.; Marston, B.J.; Breiman, R.F. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 1996, 174, 456–462.
104. Zhou, H.; Thompson, W.W.; Viboud, C.G.; Ringholz, C.M.; Cheng, P.Y.; Steiner, C.; Abedi, G.R.; Anderson, L.J.; Brammer, L.; Shay, D.K. Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008. Clin. Infect. Dis. 2012, 54, 1427–1436.
105. Nair, H.; Nokes, D.J.; Gessner, B.D.; Dherani, M.; Madhi, S.A.; Singleton, R.J.; O’Brien, K.L.; Roca, A.; Wright, P.F.; Bruce, N.; et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010, 375, 1545–1555.
106. Zhao, X.; Singh, M.; Malashkevich, V.N.; Kim, P.S. Structural characterization of the human respiratory syncytial virus fusion protein core 2. Proc. Nat. Acad. Sci. USA 2000, 97, 14172–14177.
107. Lambert, D.M.; Barney, S.; Lambert, A.L.; Guthrie, K.; Medinas, R.; Davis, D.E.; Bucy, T.; Erickson, J.; Merutka, G.; Petteway, S.R. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Nat. Acad. Sci. USA 1996, 93, 2186–2191.
108. Shepherd, N.E.; Hoang, H.N.; Desai, V.S.; Letouze, E.; Young, P.R.; Fairlie, D.P. Modular alpha-helical mimetics with antiviral activity against respiratory syncitial virus. J. Am. Chem. Soc. 2006, 128, 13284–13289.
109. Pastey, M.K.; Gower, T.L.; Spearman, P.W.; Crowe, J.E.; Graham, B.S. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat. Med. 2000, 6, 35–40.
110. Razinkov, V.; Gazumyan, A.; Nikitenko, A.; Ellestad, G.; Krishnamurthy, G. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem. Biol. 2001, 8, 645–659.
111. Douglas, J.L.; Panis, M.L.; Ho, E.; Lin, K.Y.; Krawczyk, S.H.; Grant, D.M.; Cai, R.; Swaminathan, S.; Chen, X.; Cihlar, T. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob. Agents Chemother. 2005, 49, 2460–2466.
112. Roymans, D.; de Bondt, H.L.; Arnoult, E.; Geluykens, P.; Gevers, T.; van Ginderen, M.; Verheyen, N.; Kim, H.D.; Willebrords, R.; Bonfanti, J.F.; et al. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc. Nat. Acad. Sci. USA 2010, 107, 308–313.
113. Kumar, M.; Behera, A.K.; Lockey, R.F.; Zhang, J.; Bhullar, G.; de La Cruz, C.P.; Chen, L.C.; Leong, K.W.; Huang, S.K.; Mohapatra, S.S. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum. Gene Ther. 2002, 13, 1415–1425.
114. Zhang, W.; Yang, H.; Kong, X.; Mohapatra, S.; san Juan-Vergara, H.; Hellermann, G.; Behera, S.; Singam, R.; Lockey, R.F.; Mohapatra, S.S. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. 2005, 11, 233–233.
115. McLellan, J.S.; Chen, M.; Joyce, M.G.; Sastry, M.; Stewart-Jones, G.B.E.; Yang, Y.P.; Zhang, B.S.; Chen, L.; Srivatsan, S.Zheng, A.Q.; ; et al. Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus. Science 2013, 342, 592–598.
116. McLellan, J.S.; Chen, M.; Leung, S.; Graepel, K.W.; Du, X.L.; Yang, Y.P.; Zhou, T.Q.; Baxa, U.; Yasuda, E.; Beaumont, T.; et al. Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. Science 2013, 340, 1113–1117.
117. Schepens, B.; Sedeyn, K.; Vande Ginste, L.; de Baets, S.; Schotsaert, M.; Roose, K.; Houspie, L.; van Ranst, M.; Gilbert, V.; van Rooijen, N.; et al. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol. Med. 2014, 6, 1436–1454.
118. Bird, G.H.; Boyapalle, S.; Wong, T.; Opoku-Nsiah, K.; Bedi, R.; Crannell, W.C.; Perry, A.F.; Nguyen, H.; Sampayo, V.; Devareddy, A.; et al. Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection. J. Clin. Investig. 2014, 124, 2113–2124.
119. Centers for Disease Control and Prevention. Respiratory syncytial virus activity: United States, 1999–2000 season. Morb. Mortal. Wkly. Rep. 2000, 49, 1091–1093.
120. Weiner, L.B.; Polak, M.J.; Masaquel, A.; Mahadevia, P.J. Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab among Preterm Infants Covered by Medicaid in the United States. Value Health 2011, 14, A118–A118.
121. Hall, C.B.; Powell, K.R.; Macdonald, N.E.; Gala, C.L.; Menegus, M.E.; Suffin, S.C.; Cohen, H.J. Respiratory Syncytial Viral-Infection in Children with Compromised Immune Function. N. Engl. J. Med. 1986, 315, 77–81.
122. Collins, P.L.; Melero, J.A. Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. Virus Res. 2011, 162, 80–99.
123. Krusat, T.; Streckert, H.J. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch. Virol. 1997, 142, 1247–1254.
124. Lamb, R.A. Paramyxovirus fusion: A hypothesis for changes. Virology 1993, 197, 1–11.
125. Collins, P.L.; Mottet, G. Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus. J. Gen. Virol. 1993, 74, 1445–1450.
126. Gan, S.W.; Tan, E.; Lin, X.; Yu, D.; Wang, J.; Tan, G.M.-Y.; Vararattanavech, A.; Yeo, C.Y.; Soon, C.H.; Soong, T.W.; et al. The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. J. Biol. Chem. 2012, 287, 24671–24689.
127. Taylor, C.E.; Morrow, S.; Scott, M.; Young, B.; Toms, G.L. Comparative Virulence of Respiratory Syncytial Virus Subgroup-A and Subgroup-B. Lancet 1989, 1, 777–778.
128. Mcconnochie, K.M.; Hall, C.B.; Walsh, E.E.; Roghmann, K.J. Variation in Severity of Respiratory Syncytial Virus-Infections with Subtype. J. Pediatr. 1990, 117, 52–62.
129. Hall, C.B.; Walsh, E.E.; Schnabel, K.C.; Long, C.E.; Mcconnochie, K.M.; Hildreth, S.W.; Anderson, L.J. Occurrence of Group-A and Group-B of Respiratory Syncytial Virus over 15 Years-Associated Epidemiologic and Clinical Characteristics in Hospitalized and Ambulatory Children. J. Infect. Dis. 1990, 162, 1283–1290.
130. Rixon, H.W.; Brown, G.; Aitken, J.; McDonald, T.; Graham, S.; Sugrue, R.J. The small hydrophobic (SH) protein accumulates within lipid-raft structures of the Golgi complex during respiratory syncytial virus infection. J. Gen. Virol. 2004, 85, 1153–1165.
131. Techaarpornkul, S.; Barretto, N.; Peeples, M.E. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J. Virol. 2001, 75, 6825–6834.
132. Bukreyev, A.; Whitehead, S.S.; Murphy, B.R.; Collins, P.L. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 1997, 71, 8973–8982.
133. Karron, R.A.; Buonagurio, D.A.; Georgiu, A.F.; Whitehead, S.S.; Adamus, J.E.; Harris, D.O.; Clements-Mann, M.L.; Randolph, V.B.; Udem, S.A.; Murphy, B.R.; et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. USA 1997, 94, 13961–13966.
134. Whitehead, S.S.; Bukreyev, A.; Teng, M.N.; Firestone, C.Y.; St Claire, M.; Elkins, W.R.; Collins, P.L.; Murphy, B.R. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 1999, 73, 3438–3442.
135. Jin, H.; Zhou, H.; Cheng, X.; Tang, R.; Munoz, M.; Nguyen, N. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2–2 genes are attenuated in vitro and in vivo. Virology 2000, 273, 210–218.
136. Taylor, G.; Wyld, S.; Valarcher, J.F.; Guzman, E.; Thom, M.; Widdison, S.; Buchholz, U.J. Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves. J. Gen. Virol. 2014, 95, 1244–1254.
137. Fuentes, S.; Tran, K.C.; Luthra, P.; Teng, M.N.; He, B. Function of the respiratory syncytial virus small hydrophobic protein. J. Virol. 2007, 81, 8361–8366.
138. Li, Z.; Xu, J.; Patel, J.; Fuentes, S.; Lin, Y.A.; Anderson, D.; Sakamoto, K.; Wang, L.F.; He, B.A. Function of the Small Hydrophobic Protein of J Paramyxovirus. J. Virol. 2011, 85, 32–42.
139. Jack, P.J.M.; Boyle, D.B.; Eaton, B.T.; Wang, L.F. The complete genome sequence of J virus reveals a unique genome structure in the family Paramyxoviridae. J. Virol. 2005, 79, 10690–10700.
140. Lin, Y.; Bright, A.C.; Rothermel, T.A.; He, B. Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene. J. Virol. 2003, 77, 3371–3383.
141. Wilson, R.L.; Fuentes, S.M.; Wang, P.; Taddeo, E.C.; Klatt, A.; Henderson, A.J.; He, B. Function of small hydrophobic proteins of paramyxovirus. J. Virol. 2006, 80, 1700–1709.
142. Ichinohe, T.; Pang, I.K.; Iwasaki, A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat. Immunol. 2010, 11, 404–410.
143. Ito, M.; Yanagi, Y.; Ichinohe, T. Encephalomyocarditis virus viroporin 2B activates NLRP3 inflammasome. PLoS Pathog. 2012, 8, e1002857.
144. Segovia, J.; Sabbah, A.; Mgbemena, V.; Tsai, S.Y.; Chang, T.H.; Berton, M.T.; Morris, I.R.; Allen, I.C.; Ting, J.P.Y.; Bose, S. TLR2/MyD88/NF-kappa B Pathway, Reactive Oxygen Species, Potassium Efflux Activates NLRP3/ASC Inflammasome during Respiratory Syncytial Virus Infection. PLoS ONE 2012, 7, e29695.
145. Triantafilou, K.; Kar, S.; Vakakis, E.; Kotecha, S.; Triantafilou, M. Human respiratory syncytial virus viroporin SH: A viral recognition pathway used by the host to signal inflammasome activation. Immunology 2013, 140, 87–88.
146. Gan, S.W.; Ng, L.; Xin, L.; Gong, X.; Torres, J. Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain. Protein Sci. 2008, 17, 813–820.
147. Gan, S.W.; Torres, J. Structural and functional aspects of the small hydrophobic (SH) protein in the human respiratory syncytial virus. In Human Respiratory Syncytial Virus Infection; Resch, B., Ed.; Intech: Janeza Trdine, Croatia, 2011; pp. 75–96.
148. Li, Y.; To, J.; Verdià-Baguena, C.; Dossena, S.; Surya, W.; Huang, M.; Paulmichl, M.; Liu, D.X.; Aguilella, V.M.; Torres, J. Inhibition of the Human Respiratory Syncytial Virus Small Hydrophobic Protein and Structural variations in a bicelle environment. J. Virol. 2014, 88, 11899–11914.
149. Schnell, J.R.; Chou, J.J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008, 451, 591–595.
150. Ouyang, B.; Xie, S.; Berardi, M.J.; Zhao, X.; Dev, J.; Yu, W.; Sun, B.; Chou, J.J. Unusual architecture of the p7 channel from hepatitis C virus. Nature 2013, 498, 521–525.
151. Tapia, L.I.; Shaw, C.A.; Aideyan, L.O.; Jewell, A.M.; Dawson, B.C.; Haq, T.R.; Piedra, P.A. Gene Sequence Variability of the Three Surface Proteins of Human Respiratory Syncytial Virus (HRSV) in Texas. PLoS ONE 2014, 9, e90786.
152. Chen, M.D.; Vazquez, M.; Buonocore, L.; Kahn, J.S. Conservation of the respiratory syncytial virus SH gene. J. Infect. Dis. 2000, 182, 1228–1233.
153. Collins, P.L.; Olmsted, R.A.; Johnson, P.R. The small hydrophobic protein of human respiratory syncytial virus: Comparison between antigenic subgroups A and B. J. Gen. Virol. 1990, 71, 1571–1576.
154. Takeuchi, K.; Tanabayashi, K.; Hishiyama, M.; Yamada, A. The mumps virus SH protein is a membrane protein and not essential for virus growth. Virology 1996, 225, 156–162.
155. Elango, N.; Kovamees, J.; Varsanyi, T.M.; Norrby, E. Messenger-RNA Sequence and Deduced Amino-Acid Sequence of the Mumps-Virus Small Hydrophobic Protein Gene. J. Virol. 1989, 63, 1413–1415.
156. Low, K.W.; Tan, T.; Ng, K.; Tan, B.H.; Sugrue, R.J. The RSV F and G glycoproteins interact to form a complex on the surface of infected cells. Biochem. Biophys. Res. Commun. 2008, 366, 308–313.
157. Rixon, H.W.; Brown, G.; Murray, J.T.; Sugrue, R.J. The respiratory syncytial virus small hydrophobic protein is phosphorylated via a mitogen-activated protein kinase p38-dependent tyrosine kinase activity during virus infection. J. Gen. Virol. 2005, 86, 375–384.
158. Schlender, J.; Zimmer, G.; Herrler, G.; Conzelmann, K.K. Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV infection. J. Virol. 2003, 77, 4609–4616.
159. Karger, A.; Schmidt, U.; Buchholz, U.J. Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. J. Gen. Virol. 2001, 82, 631–640.
160. Li, Y.; Jain, N.; Limpanawat, S.; To, J.; Quistgaard, E.M.; Nordlund, P.; Thanabalu, T.; Torres, J. Interaction between human BAP31 and Respiratory Syncytial Virus Small Hydrophobic (SH) protein. Virology 2015, 482, 105–110.
161. Wang, B.; Heath-Engel, H.; Zhang, D.; Nguyen, N.; Thomas, D.Y.; Hanrahan, J.W.; Shore, G.C. BAP31 Interacts with Sec61 Translocons and Promotes Retrotranslocation of CFTR∆F508 via the Derlin-1 Complex. Cell 2008, 133, 1080–1092.
162. Adachi, T.; Schamel, W.W.; Kim, K.M.; Watanabe, T.; Becker, B.; Nielsen, P.J.; Reth, M. The specificity of association of the IgD molecule with the accessory proteins BAP31/BAP29 lies in the IgD transmembrane sequence. EMBO J. 1996, 15, 1534–1541.
163. Quistgaard, E.M.; Low, C.; Moberg, P.; Guettou, F.; Maddi, K.; Nordlund, P. Structural and biophysical characterization of the cytoplasmic domains of human BAP29 and BAP31. PLoS ONE 2013, 8, e71111.
164. Ng, F.W.H.; Nguyen, M.; Kwan, T.; Branton, P.E.; Nicholson, D.W.; Cromlish, J.A.; Shore, G.C. p28 Bap31, a Bcl-2/Bcl-X-L- and procaspase-8-associated protein in the endoplasmic reticulum. J. Cell Biol. 1997, 139, 327–338.
165. Breckenridge, D.G.; Nguyen, M.; Kuppig, S.; Reth, M.; Shore, G.C. The procaspase-8 isoform, procaspase-8L, recruited to the BAP31 complex at the endoplasmic reticulum. Proc. Nat. Acad. Sci. USA 2002, 99, 4331–4336.
166. Breckenridge, D.G.; Stojanovic, M.; Marcellus, R.C.; Shore, G.C. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. J. Cell Biol. 2003, 160, 1115–1127.
167. Rosati, E.; Sabatini, R.; Rampino, G.; De Falco, F.; Di Ianni, M.; Falzetti, F.; Fettucciari, K.; Bartoli, A.; Screpanti, I.; Marconi, P. Novel targets for endoplasmic reticulum stress-induced apoptosis in B-CLL. Blood 2010, 116, 2713–2723.
168. Iwasawa, R.; Mahul-Mellier, A.L.; Datler, C.; Pazarentzos, E.; Grimm, S. Fis1 and Bap31 bridge the mitochondria-ER interface to establish a platform for apoptosis induction. EMBO J. 2011, 30, 556–568.
169. Kabsch, K.; Mossadegh, N.; Kohl, A.; Komposch, G.; Schenkel, J.; Alonso, A.; Tomakidi, P. The HPV-16 E5 protein inhibits TRAIL- and FasL-mediated apoptosis in human keratinocyte raft cultures. Intervirology 2004, 47, 48–56.
170. Regan, J.A.; Laimins, L.A. Bap31 is a novel target of the human papillomavirus E5 protein. J. Virol. 2008, 82, 10042–10051.
171. Walensky, L.D.; Bird, G.H. Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress. J. Med. Chem. 2014, 57, 6275–6288.
172. Bellmann-Sickert, K.; Stone, T.A.; Poulsen, B.E.; Deber, C.M. Efflux by Small Multidrug Resistance Proteins is Inhibited by Membrane-Interactive Helix-Stapled Peptides. J. Biol. Chem. 2014, 290, 1752–1759.